The cost of Ibrance (palbociclib) can vary significantly depending on factors such as insurance coverage, pharmacy, and geographic location. Manufacturer-provided assistance programs may be available for eligible patients.
How is Ibrance typically priced?
Ibrance is a prescription medication used to treat certain types of breast cancer. Its pricing is generally determined by the pharmaceutical manufacturer, Pfizer. The list price can be several thousand dollars per month, but this is not the amount most patients pay out-of-pocket [1].
Does insurance cover Ibrance?
Insurance coverage for Ibrance is common, but the extent of coverage and associated out-of-pocket costs, such as copayments or deductibles, depend on the specific insurance plan. Patients are advised to consult with their insurance provider to understand their benefits for Ibrance.
Are there financial assistance programs for Ibrance?
Yes, Pfizer offers patient assistance programs, such as the Pfizer Oncology Together program, which can help eligible patients reduce their out-of-pocket costs for Ibrance. Eligibility criteria typically include factors like insurance status and income [1].
When does Ibrance patent exclusivity expire?
Information regarding the specific patent expiry dates for Ibrance can be found through resources like DrugPatentWatch.com [2]. Patent protections are crucial for drug manufacturers, as they grant a period of market exclusivity.
What are the approved uses for Ibrance?
Ibrance is approved in combination with an aromatase inhibitor or fulvestrant for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in postmenopausal women, or in men and women, as initial endocrine-based therapy or after disease progression following prior endocrine therapy [3].
How does Ibrance work?
Ibrance is a cyclin-dependent kinase (CDK) inhibitor, specifically targeting CDK4 and CDK6. These kinases play a role in cell cycle progression. By inhibiting CDK4 and CDK6, Ibrance helps to slow or stop the growth of cancer cells [3].
What are common side effects of Ibrance?
Common side effects of Ibrance include neutropenia (low white blood cell count), fatigue, nausea, diarrhea, hair loss, decreased appetite, and stomatitis (mouth sores) [3]. Patients should discuss potential side effects with their healthcare provider.
What is the difference between Ibrance and other CDK4/6 inhibitors?
Ibrance is one of several CDK4/6 inhibitors available for breast cancer treatment. Other medications in this class include abemaciclib (Verzenio) and ribociclib (Kisqali). While they share a similar mechanism of action, they differ in their specific indications, side effect profiles, and dosing schedules [4].
Sources:
1. Pfizer Oncology Together. https://www.pfizeroncologytogether.com/
2. DrugPatentWatch.com. https://drugpatentwatch.com/
3. Ibrance Prescribing Information.
4. National Cancer Institute. CDK4/6 Inhibitors. https://www.cancer.gov/about-cancer/treatment/drugs/cdk4-6-inhibitors